

**Priority question for written answer P-001479/2021
to the Commission**

Rule 138

Milan Brglez (S&D), Tanja Fajon (S&D)

Subject: Transparency in the procurement and supply of COVID-19 vaccines and vaccination rates in the Member States

In order to obtain COVID-19 vaccines as soon as possible and ensure a common and centralised approach to ensuring supplies, last June the Commission set out the EU's vaccine strategy. One of the main principles of that strategy is the centralised procurement of vaccines approved at EU level, together with equal access and fair distribution between Member States on the basis of population size.

Delays and complications in the supply of vaccines, individual Member States deciding to procure vaccines not (yet) approved in the EU, and recent criticisms by certain heads of state alleging unequal access to COVID-19 vaccines are undermining the joint approach and the effectiveness of the management of the pandemic in the EU. Given this state of affairs, greater transparency in the procedures for procuring and distributing COVID-19 vaccines seems to be the only possible response in order to maintain a common approach and strengthen people's trust in its effectiveness and efficiency.

1. Does the Commission intend to ensure greater transparency in relation to orders, actual deliveries and the vaccination rates in each Member State, and if so how?
2. How does the Commission respond to criticisms of the work of the EU vaccine steering committee, which the leaders of some Member State say is responsible for the uneven distribution of vaccines between Member States?